OBJECTIVES: Conventional T2 weighted MRI studies have highlighted the fact that the presence of clinically silent brain lesions increases the risk of developing clinically definite multiple sclerosis after an isolated syndrome of the optic nerve, brain stem, or spinal cord. The objectives of the present study are: (1) to show whether or not these patients also have asymptomatic abnormalities of the spinal cord, and (2) to recruit a new cohort of such patients using high resolution MRI of both brain and spinal cord. METHODS: The brain was imaged in the axial plane with 3 mm thick contiguous slices using a proton density and T2 weighted fast spin echo (FSE) sequence; a T1 weighted sequence after the injection of gadolinium-DTPA; and a fast fluid attenuated inversion recovery (fFLAIR) sequence. The spinal cord was imaged in the sagittal plane with 3 mm thick slices using a T2 weighted FSE and a T1 weighted gadolinium enhanced sequence. RESULTS: Thirty three patients, mean age 31 (16-46) were recruited. There were 14 men and 19 women. Brain MRI was abnormal in 22 (67%); no patient was seen with abnormalities on only one or other sequence. Six patients (18%) displayed one or more gadolinium enhancing lesions on brain MRI. In the spinal cord, nine (27%) patients displayed one or more clinically silent lesions on FSE. Two patients showed one and two gadolinium enhancing lesions in the spinal cord respectively. CONCLUSION: This high incidence of spinal cord lesions emphasises that asymptomatic demyelinating lesions may also involve clinically eloquent pathways. Follow up studies are required to determine their prognostic importance.
OBJECTIVES: Conventional T2 weighted MRI studies have highlighted the fact that the presence of clinically silent brain lesions increases the risk of developing clinically definite multiple sclerosis after an isolated syndrome of the optic nerve, brain stem, or spinal cord. The objectives of the present study are: (1) to show whether or not these patients also have asymptomatic abnormalities of the spinal cord, and (2) to recruit a new cohort of such patients using high resolution MRI of both brain and spinal cord. METHODS: The brain was imaged in the axial plane with 3 mm thick contiguous slices using a proton density and T2 weighted fast spin echo (FSE) sequence; a T1 weighted sequence after the injection of gadolinium-DTPA; and a fast fluid attenuated inversion recovery (fFLAIR) sequence. The spinal cord was imaged in the sagittal plane with 3 mm thick slices using a T2 weighted FSE and a T1 weighted gadolinium enhanced sequence. RESULTS: Thirty three patients, mean age 31 (16-46) were recruited. There were 14 men and 19 women. Brain MRI was abnormal in 22 (67%); no patient was seen with abnormalities on only one or other sequence. Six patients (18%) displayed one or more gadolinium enhancing lesions on brain MRI. In the spinal cord, nine (27%) patients displayed one or more clinically silent lesions on FSE. Two patients showed one and two gadolinium enhancing lesions in the spinal cord respectively. CONCLUSION: This high incidence of spinal cord lesions emphasises that asymptomatic demyelinating lesions may also involve clinically eloquent pathways. Follow up studies are required to determine their prognostic importance.
Authors: V Martinelli; G Comi; M Filippi; A Poggi; B Colombo; M Rodegher; G Scotti; F Triulzi; N Canal Journal: Acta Neurol Scand Date: 1991-09 Impact factor: 3.209
Authors: W T Yuh; E E Marsh; A K Wang; J W Russell; F Chiang; T M Koci; T J Ryals Journal: AJNR Am J Neuroradiol Date: 1992 Jan-Feb Impact factor: 3.825
Authors: R W Beck; P A Cleary; J D Trobe; D I Kaufman; M J Kupersmith; D W Paty; C H Brown Journal: N Engl J Med Date: 1993-12-09 Impact factor: 91.245
Authors: S P Morrissey; D H Miller; B E Kendall; D P Kingsley; M A Kelly; D A Francis; D G MacManus; W I McDonald Journal: Brain Date: 1993-02 Impact factor: 13.501
Authors: J W Thorpe; D Kidd; B E Kendall; P S Tofts; G J Barker; A J Thompson; D G MacManus; W I McDonald; D H Miller Journal: Neurology Date: 1993-12 Impact factor: 9.910
Authors: D Kidd; J W Thorpe; A J Thompson; B E Kendall; I F Moseley; D G MacManus; W I McDonald; D H Miller Journal: Neurology Date: 1993-12 Impact factor: 9.910
Authors: D H Miller; N Buchanan; G Barker; S P Morrissey; B E Kendall; P Rudge; M Khamashta; G R Hughes; W I McDonald Journal: J Neurol Date: 1992-10 Impact factor: 4.849
Authors: R N Heard; S M Teutsch; B H Bennetts; S D Lee; E M Deane; G J Stewart Journal: J Neurol Neurosurg Psychiatry Date: 1999-11 Impact factor: 10.154
Authors: M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban Journal: AJNR Am J Neuroradiol Date: 2000-04 Impact factor: 3.825
Authors: G Schulte-Altedorneburg; F Ahlhelm; A Zimmer; J Viera; A Nabhan; D-A Clevert; A Haass; W Reith Journal: Radiologe Date: 2006-12 Impact factor: 0.635
Authors: Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi Journal: Invest Ophthalmol Vis Sci Date: 2009-02-21 Impact factor: 4.799